share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  08/14 15:35

Moomoo AI 已提取核心信息

Aclarion, Inc., a healthcare technology company, reported financial results for the quarter ended June 30, 2024. Revenue for the quarter was $10,971, a decrease from $17,072 in the same period last year. The company experienced a gross loss of $12,323 compared to a loss of $2,229 in the previous year, primarily due to the conclusion of certain clinical activities. Operating expenses totaled $1,123,238, with a decrease in general and administrative expenses from $946,175 to $696,099. The net loss for the quarter was $1,238,077, an improvement from a net loss of $1,464,557 in the prior year. The company's cash position, including restricted cash, was $1,182,687, which is expected to fund operations into the third quarter of 2024. Aclarion's future plans include raising additional funds to continue technology development, with management actively seeking funding options. The company's financial statements reflect the impact of a reverse stock split and the issuance of new shares through a public offering and an equity line agreement.
Aclarion, Inc., a healthcare technology company, reported financial results for the quarter ended June 30, 2024. Revenue for the quarter was $10,971, a decrease from $17,072 in the same period last year. The company experienced a gross loss of $12,323 compared to a loss of $2,229 in the previous year, primarily due to the conclusion of certain clinical activities. Operating expenses totaled $1,123,238, with a decrease in general and administrative expenses from $946,175 to $696,099. The net loss for the quarter was $1,238,077, an improvement from a net loss of $1,464,557 in the prior year. The company's cash position, including restricted cash, was $1,182,687, which is expected to fund operations into the third quarter of 2024. Aclarion's future plans include raising additional funds to continue technology development, with management actively seeking funding options. The company's financial statements reflect the impact of a reverse stock split and the issuance of new shares through a public offering and an equity line agreement.
医疗科技公司艾克莱里昂公布了截至2024年6月30日的季度财务报告。该季度营业收入为10,971美元，较去年同期的17,072美元有所下降。公司毛损失为12,323美元，相比上一年的2,229美元亏损，主要是由于某些临床活动的结束。营业费用总额为1,123,238美元，其中一般和行政费用降至696,099美元，而上年同期为946,175美元。该季度的净亏损为1,238,077美元，较前一年的1,464,557美元的净亏损有所改善。公司的现金头寸，包括受限现金在内，为1,182,687美元，预计可以支持运营到2024年第三季度。艾克莱里昂未来的计划包括筹集额外的资金以继续科技的开发，管理层积极寻求筹资选择。公开发行和股权额度协议发行新股以及股票拆分对公司的财务报表产生了影响。
医疗科技公司艾克莱里昂公布了截至2024年6月30日的季度财务报告。该季度营业收入为10,971美元，较去年同期的17,072美元有所下降。公司毛损失为12,323美元，相比上一年的2,229美元亏损，主要是由于某些临床活动的结束。营业费用总额为1,123,238美元，其中一般和行政费用降至696,099美元，而上年同期为946,175美元。该季度的净亏损为1,238,077美元，较前一年的1,464,557美元的净亏损有所改善。公司的现金头寸，包括受限现金在内，为1,182,687美元，预计可以支持运营到2024年第三季度。艾克莱里昂未来的计划包括筹集额外的资金以继续科技的开发，管理层积极寻求筹资选择。公开发行和股权额度协议发行新股以及股票拆分对公司的财务报表产生了影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间